Globe Newswire04.06.17
Osiris Therapeutics Inc., a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, has developed cutting-edge technology enabling the preservation of living cells and tissues at ambient temperatures.
Historically, cryopreservation was the only available method that allowed for long-term preservation of living cells and tissues. However, cryopreservation requires ultra-low-temperature freezers and dry ice or liquid nitrogen for storage, which limits the widespread use of cellular therapies. To address this limitation, Osiris has developed Prestige Lyotechnology. Unlike all other known lyophilization methods, Prestige Lyotechnology enables the preservation of living cells within tissues while stored at ambient temperatures. Moreover, the manufacturing of lyopreserved living tissues with Prestige Lyotechnology is scalable and can be applied to many different cell and tissue types. Placental products will be the focus of the company’s first application of Prestige Lyotechnology.
“This novel technology developed by Osiris will benefit the entire field of cellular therapies. It is expected to accelerate development, commercialization and widespread use of living cell and tissue therapies,” said Alla Danilkovitch, chief scientific officer at Osiris. “Through more than two decades of basic and clinical research, Osiris has not only defined the science and potential of cellular regenerative therapies, but has also created a body of work, advancing the medical community’s understanding of cellular technology. With the introduction of Prestige Lyotechnology, Osiris is bringing these innovative cellular therapies to more patients to address a wide range of unmet medical needs.”
Osiris Therapeutics, based in Columbia, Md., researches, develops, and markets regenerative medicine products. Having developed the world’s first approved stem cell drug, the company continues to advance its research and development in biotechnology by focusing on innovation in regenerative medicine—including bioengineering, stem cell research and viable tissue based products. Osiris has achieved commercial success with products in wound care, orthopedics, and sports medicine, including Grafix, Stravix, BIO4, and Cartiform. Osiris, Grafix, Stravix and Cartiform are trademarks of Osiris Therapeutics Inc., and BIO4 is a trademark of Howmedica Osteonics Corp.
Historically, cryopreservation was the only available method that allowed for long-term preservation of living cells and tissues. However, cryopreservation requires ultra-low-temperature freezers and dry ice or liquid nitrogen for storage, which limits the widespread use of cellular therapies. To address this limitation, Osiris has developed Prestige Lyotechnology. Unlike all other known lyophilization methods, Prestige Lyotechnology enables the preservation of living cells within tissues while stored at ambient temperatures. Moreover, the manufacturing of lyopreserved living tissues with Prestige Lyotechnology is scalable and can be applied to many different cell and tissue types. Placental products will be the focus of the company’s first application of Prestige Lyotechnology.
“This novel technology developed by Osiris will benefit the entire field of cellular therapies. It is expected to accelerate development, commercialization and widespread use of living cell and tissue therapies,” said Alla Danilkovitch, chief scientific officer at Osiris. “Through more than two decades of basic and clinical research, Osiris has not only defined the science and potential of cellular regenerative therapies, but has also created a body of work, advancing the medical community’s understanding of cellular technology. With the introduction of Prestige Lyotechnology, Osiris is bringing these innovative cellular therapies to more patients to address a wide range of unmet medical needs.”
Osiris Therapeutics, based in Columbia, Md., researches, develops, and markets regenerative medicine products. Having developed the world’s first approved stem cell drug, the company continues to advance its research and development in biotechnology by focusing on innovation in regenerative medicine—including bioengineering, stem cell research and viable tissue based products. Osiris has achieved commercial success with products in wound care, orthopedics, and sports medicine, including Grafix, Stravix, BIO4, and Cartiform. Osiris, Grafix, Stravix and Cartiform are trademarks of Osiris Therapeutics Inc., and BIO4 is a trademark of Howmedica Osteonics Corp.